Patents by Inventor Jeff Sperinde

Jeff Sperinde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
    Publication number: 20230062274
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 2, 2023
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
  • Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
    Patent number: 11579148
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: February 14, 2023
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
    Patent number: 11401344
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 2, 2022
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
  • Methods of determining patient response by measurement of HER-3
    Patent number: 10775382
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: September 15, 2020
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Her2 diagnostic methods
    Patent number: 10416162
    Abstract: In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 17, 2019
    Assignee: Monogram Biosciences, Inc.
    Inventors: Weidong Huang, Jeff Sperinde, Michael Bates, Colombe Chappey, John William Winslow
  • Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
    Publication number: 20190257836
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Application
    Filed: October 22, 2018
    Publication date: August 22, 2019
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • Methods of producing antibodies specific for p95
    Patent number: 10273308
    Abstract: The disclosure provides methods of making antibodies specific for p95.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: April 30, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
    Publication number: 20190055319
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
  • Methods of Determining Patient Response by Measurement of HER-3
    Publication number: 20180164319
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Application
    Filed: August 21, 2017
    Publication date: June 14, 2018
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Methods of determining patient response by measurement of HER-3 and P95
    Patent number: 9766242
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex and the presence and/or amount of p95 in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 19, 2017
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Methods of Determining Patient Response by Measurement of HER-2 Expression
    Publication number: 20170082626
    Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.
    Type: Application
    Filed: June 15, 2016
    Publication date: March 23, 2017
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Methods of Determining Patient Response by Measurement of HER-3
    Publication number: 20160061839
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Application
    Filed: July 17, 2015
    Publication date: March 3, 2016
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Methods of Producing Antibodies Specific for p95
    Publication number: 20150376293
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95, and methods of making such antibodies.
    Type: Application
    Filed: June 12, 2015
    Publication date: December 31, 2015
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • HER-3 antibodies and methods of use
    Patent number: 9110066
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: August 18, 2015
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
    Patent number: 9081019
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: July 14, 2015
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • Methods of Determining Patient Response by Measurement of HER-2 Expression
    Publication number: 20140370523
    Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.
    Type: Application
    Filed: July 2, 2014
    Publication date: December 18, 2014
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Stephen J. Williams
  • Methods and Assays for Measuring p95 and/or p95 Complexes in a Sample and Antibodies Specific for p95
    Publication number: 20130316380
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.
    Type: Application
    Filed: June 6, 2013
    Publication date: November 28, 2013
    Applicant: Laboratory Corporation of America Holdings
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin
  • Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
    Patent number: 8470542
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: June 25, 2013
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin
  • Methods of determining patient response by measurement of Her-3
    Patent number: 8349574
    Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: January 8, 2013
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Michael Bates, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Stephen J. Williams
  • Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
    Publication number: 20120295259
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Application
    Filed: May 21, 2012
    Publication date: November 22, 2012
    Applicant: LABORATORY CORPORATION OF AMERICA HOLDINGS
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates